

# Efavirenz + emtricitabine + tenofovir



Essential medicine status ✓

Section: [6. Anti-infective medicines](#) > [6.4. Antiviral medicines](#) > [6.4.2. Antiretrovirals](#) > [6.4.2.5. Fixed-dose combinations of antiretrovirals](#)

ATC codes: **J05AR06**

Indication	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified <b>ICD11 code: 1C62.Z</b>
INN	Efavirenz + emtricitabine + tenofovir
Medicine type	Chemical agent
List type	Core
Formulations	Oral > Solid: 600 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
EML status history	First added in 2007 ( <a href="#">TRS 946</a> ) Changed in 2021 ( <a href="#">TRS 1035</a> )
Sex	All
Age	Adolescents and adults
Therapeutic alternatives	efavirenz + lamivudine + tenofovir (ATC codes: J05AR11)
Patent information	Main patents have expired but secondary patents might remain active in some jurisdictions. For more information on specific patents and license status for developing countries visit <a href="http://www.MedsPal.org">www.MedsPal.org</a> Read more <a href="#">about patents.</a>

Wikipedia [Efavirenz + emtricitabine + tenofovir](#)

DrugBank [Efavirenz](#) ,  
[Emtricitabine](#) ,  
[Tenofovir disoproxil](#)

## Summary of evidence and Expert Committee recommendations

Following the review of square box listings on the EML and EMLc, the Expert Committee recommended lamivudine be specified as a therapeutic alternative for the emtricitabine component under the square box listing for efavirenz + emtricitabine + tenofovir on the EML.

